| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Giuseppe Manfroni | Q39062747 |
| Violetta Cecchetti | Q39062804 | ||
| Maria Letizia Barreca | Q39062826 | ||
| P2093 | author name string | Nunzio Iraci | |
| P2860 | cites work | A fast flexible docking method using an incremental construction algorithm. | Q52298930 |
| Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) | Q54260077 | ||
| General atomic and molecular electronic structure system | Q56017006 | ||
| PLS-regression: a basic tool of chemometrics | Q56454404 | ||
| Structural biology of hepatitis C virus | Q56762917 | ||
| Semianalytical treatment of solvation for molecular mechanics and dynamics | Q56866446 | ||
| Molecular Descriptors for Chemoinformatics | Q56978888 | ||
| Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 | Q57976081 | ||
| Comparative Molecular Field Analysis Using GRID Force-Field and GOLPE Variable Selection Methods in a Study of Inhibitors of Glycogen Phosphorylase b | Q58137179 | ||
| Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D-QSAR Problems | Q58137190 | ||
| The Protein Data Bank | Q24515306 | ||
| DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases | Q27231136 | ||
| Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme | Q27477662 | ||
| Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model | Q27484513 | ||
| Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus | Q27486092 | ||
| 1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus | Q27490956 | ||
| Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-ray crystallographic study | Q27643731 | ||
| High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations | Q27649731 | ||
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor | Q27653726 | ||
| Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase | Q27655827 | ||
| Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids | Q27657126 | ||
| Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides | Q27657188 | ||
| Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase | Q27657737 | ||
| Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors | Q27662842 | ||
| Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B | Q27664993 | ||
| Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 | ||
| Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges | Q28096294 | ||
| Development and validation of a genetic algorithm for flexible docking | Q28236574 | ||
| Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy | Q28251042 | ||
| Structural biology and drug discovery | Q28259532 | ||
| Pharmacophore-based virtual screening | Q28275364 | ||
| Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes | Q28292827 | ||
| AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility | Q29547658 | ||
| Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes | Q29616736 | ||
| A critical assessment of docking programs and scoring functions | Q29616761 | ||
| Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening | Q29617343 | ||
| The global burden of hepatitis C | Q29620138 | ||
| Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy | Q29620140 | ||
| Novel procedure for modeling ligand/receptor induced fit effects. | Q30352584 | ||
| A computational procedure for determining energetically favorable binding sites on biologically important macromolecules | Q30406755 | ||
| Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking | Q30822076 | ||
| GFscore: a general nonlinear consensus scoring function for high-throughput docking | Q33251333 | ||
| Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors | Q33270582 | ||
| Docking ligands into flexible and solvated macromolecules. 2. Development and application of fitted 1.5 to the virtual screening of potential HCV polymerase inhibitors | Q33323904 | ||
| Approaches for the development of antiviral compounds: the case of hepatitis C virus | Q33388715 | ||
| Insight into ligand selectivity in HCV NS5B polymerase: molecular dynamics simulations, free energy decomposition and docking | Q33452082 | ||
| Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase | Q33509716 | ||
| Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. | Q33631936 | ||
| Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus | Q33852451 | ||
| The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure | Q34326042 | ||
| Computational methods for biomolecular docking. | Q34396832 | ||
| Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors | Q34608988 | ||
| Molecular dynamics simulations of biomolecules | Q34799927 | ||
| Computer tools in the discovery of HIV-1 integrase inhibitors | Q36145611 | ||
| Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. | Q36509228 | ||
| Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. | Q37014096 | ||
| Docking-based virtual screening: recent developments. | Q37411223 | ||
| Antiviral resistance and specifically targeted therapy for HCV (STAT-C). | Q37497122 | ||
| Successful applications of computer aided drug discovery: moving drugs from concept to the clinic | Q37636258 | ||
| Investigational drugs for hepatitis C. | Q37650377 | ||
| Pharmacophore modeling and applications in drug discovery: challenges and recent advances | Q37723606 | ||
| Pharmacophore based drug design approach as a practical process in drug discovery | Q37725042 | ||
| Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy | Q37726075 | ||
| New NS5B polymerase inhibitors for hepatitis C. | Q37772518 | ||
| NS5B RNA dependent RNA polymerase inhibitors: the promising approach to treat hepatitis C virus infections | Q37790748 | ||
| Accounting for induced-fit effects in docking: what is possible and what is not? | Q37799620 | ||
| Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges | Q37855859 | ||
| Pharmacophore-based virtual screening: a review of recent applications | Q38028528 | ||
| On some aspects of validation of predictive quantitative structure-activity relationship models | Q38089131 | ||
| A cell-based reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA polymerase | Q39716427 | ||
| Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor | Q39793108 | ||
| Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step | Q39827052 | ||
| Advanced in silico approaches in antiviral research | Q39891451 | ||
| Overview of computational methods employed in early-stage drug discovery. | Q39991348 | ||
| Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors | Q40357821 | ||
| Specifically targeted antiviral therapy for hepatitis C virus | Q42909514 | ||
| Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients | Q42977217 | ||
| Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D- QSAR and molecular docking studies | Q42978980 | ||
| Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides | Q42982707 | ||
| Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency | Q42983781 | ||
| Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation | Q42986580 | ||
| Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy | Q42987570 | ||
| Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors | Q42987720 | ||
| Discovery of 4H-pyrazolo[1,5-a]pyrimidin-7-ones as potent inhibitors of hepatitis C virus polymerase | Q42990171 | ||
| Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors | Q42995377 | ||
| Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics | Q42998095 | ||
| Discovery of novel dialkyl substituted thiophene inhibitors of HCV by in silico screening of the NS5B RdRp | Q43037862 | ||
| 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors | Q44016857 | ||
| LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites | Q44247315 | ||
| Comparison of a QM/MM force field and molecular mechanics force fields in simulations of alanine and glycine "dipeptides" (Ace-Ala-Nme and Ace-Gly-Nme) in water in relation to the problem of modeling the unfolded peptide backbone in solution | Q44296010 | ||
| Ligand-based structural hypotheses for virtual screening | Q44400932 | ||
| 3-Hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymerase | Q45293326 | ||
| Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors | Q45391940 | ||
| Hepatitis C virus NS5B polymerase: QM/MM calculations show the important role of the internal energy in ligand binding | Q45397163 | ||
| Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. | Q45959420 | ||
| Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. | Q46460113 | ||
| Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins | Q47746759 | ||
| Docking ligands into flexible and solvated macromolecules. 3. Impact of input ligand conformation, protein flexibility, and water molecules on the accuracy of docking programs | Q47948640 | ||
| Identification of a series of novel derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure. | Q50911540 | ||
| Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships | Q51614833 | ||
| P433 | issue | 8 | |
| P921 | main subject | hepatitis C | Q154869 |
| in silico | Q192572 | ||
| Hepatitis C virus | Q708693 | ||
| drug discovery | Q1418791 | ||
| P304 | page(s) | 1027-1055 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Future Medicinal Chemistry | Q19280078 |
| P1476 | title | Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development | |
| P478 | volume | 3 |
| Q37731812 | 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase |
| Q47845542 | 5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry |
| Q30316803 | Analysis of the Resistance of Hepatitis C Virus NS5B Polymerase Inhibitors via Docking and Molecular Dynamics Simulation |
| Q32183060 | Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase |
| Q28538562 | Cofactor-independent phosphoglycerate mutase from nematodes has limited druggability, as revealed by two high-throughput screens |
| Q44282962 | Computational medicinal chemistry: part III. |
| Q28553112 | Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking |
| Q34467694 | Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors |
| Q39487360 | Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors |
| Q42228191 | Exploiting ChEMBL database to identify indole analogs as HCV replication inhibitors |
| Q42986267 | Maria Letizia Barreca on hepatitis C virus treatment and control |
| Q34372464 | New pyrazolobenzothiazine derivatives as hepatitis C virus NS5B polymerase palm site I inhibitors |
| Q34587192 | Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication |
| Q37638410 | The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors |
| Q38109800 | Use of allosteric targets in the discovery of safer drugs |
Search more.